Aspireo Pharmaceuticals
Treatments for Conditions Resulting from Hormone-active Tumors
Company Overview
Snapshot
Founded in January 2010, Aspireo Pharmaceuticals operates with 1–10 employees. The company's Somatoprim (DG3173) program was acquired by Cortendo for $30 million in May 2015.
Business overview
Aspireo Pharmaceuticals is a biopharmaceutical company focused on developing a novel somatostatin analog (SSA), Somatoprim (DG3173), for treating diseases caused by hormone-active tumors, including acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing's disease, and diabetic retinopathy. The company's technology utilizes a novel amino acid composition and an innovative backbone cyclization for peptide stabilization, aiming to offer an improved side effect profile compared to existing SSAs. Aspireo operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its drug discovery and development efforts.
Strategic signal
In May 2015, Aspireo Pharmaceuticals' Somatoprim (DG3173) program was acquired by Cortendo for $30 million. This acquisition signals a significant validation of Aspireo's proprietary somatostatin analog technology and its potential in the treatment of hormone-active tumors, demonstrating a successful exit for the program and indicating strong market interest in novel biopharmaceutical solutions for endocrine disorders.
Log in to access full profile ›Company Intelligence Q&A
- What is Aspireo Pharmaceuticals' primary focus?
- Aspireo Pharmaceuticals is focused on developing a novel somatostatin analog (SSA) for treating conditions resulting from hormone-active tumors, such as acromegaly and neuroendocrine tumors.
- What is Somatoprim (DG3173)?
- Somatoprim (DG3173) is Aspireo Pharmaceuticals' sole development compound, a novel and proprietary somatostatin analog based on a unique amino acid composition and an innovative backbone cyclization technology for peptide stabilization.
- What was a significant corporate development for Aspireo Pharmaceuticals in 2015?
- In May 2015, Aspireo Pharmaceuticals' Somatoprim (DG3173) program was acquired by Cortendo for $30 million.
- Who was Aspireo Pharmaceuticals' investor?
- Aspireo Pharmaceuticals' investor was TVM Capital, a dedicated provider of equity capital to the international pharmaceutical, biopharmaceutical, medical technology, and healthcare diagnostics industries.
- What is the current status of Aspireo Pharmaceuticals?
- Aspireo Pharmaceuticals is currently listed as Non Active as of May 2015.